Regulatory progress on Galderma's botulinum toxin candidate keeps competitive pressure on Allergan and Revance.
Galderma has updated the FDA on its Biologics License Application (BLA) for relabotulinum toxinA, signaling continued advancement toward potential approval. Relabotulinum is a recombinant botulinum toxin designed to offer a differentiated potency and diffusion profile compared to Botox (onabotulinumtoxinA) and Revance's DaxibotulinumtoxinA (Daxxify).
The competitive toxin market is consolidating: AbbVie's Botox dominates via Allergan Aesthetics and the Allē loyalty program; Revance holds a smaller but growing share with Daxxify's longer duration (6 months vs. Botox's 3–4 months); and Evolus' Jeuveau captures price-sensitive segments. Galderma's entry, if approved, introduces a third major player and could trigger pricing pressure across the category—similar to what occurred when Jeuveau launched in 2019.
Relabotulinum's BLA progress adds a third major toxin competitor, threatening Botox's pricing and loyalty dominance.
For practices, regulatory approval of relabotulinum would expand sourcing options and potentially unlock new rebate or loyalty structures from Galderma, though Botox's entrenched position and Allē's rebate ecosystem remain formidable barriers.
Source: original report ↗
Free alerts Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo Join the owners who run ahead of the industry. Cancel anytime, one click.
